Search Results - "Coats, ME"

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis by RUDICK, R. A, SIMONIAN, N. A, MASS, M. K, RICHERT, J. R, SALAZAR, A. M, MUNSCHBAUER, F. E, COOKFAIR, D. L, SIMON, J. H, JACOBS, L. D, ALAM, J. A, CAMPION, M, SCARAMUCCI, J. O, JONES, W, COATS, M. E, GOODKIN, D. E, WEINSTOCK-GUTTMAN, B, HERNDON, R. M

Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis by Herndon, Robert M, Rudick, Richard A, Munschauer, Frederick E, Mass, Michele K, Salazar, Andres M, Coats, Michael E, Labutta, Robert, Richert, John R, Cohan, Stanley L, Genain, Claude, Goodkin, Donald, Toal, Martin, Riester, Katherine

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis by Rudick, Richard A., Cookfair, Diane L., Simonian, Nancy A., Ransohoff, Richard M., Richert, John R., Jacobs, Lawrence D., Herndon, Robert M., Salazar, Andres M., Fischer, Jill S., Granger, Carl V., Goodkin, Donald E., Simon, Jack H., Bartoszak, David M., Bourdette, Dennis N., Braiman, Jonathan, Brownscheidle, Carol M., Coats, Michael E., Cohan, Stanley L., Dougherty, David S., Kinkel, Revere P., Mass, Michele K., Munchsauer, Frederick E., O'Reilly, Kathy, Priore, Roger L., Pullicino, Patrick M., Scherokman, Barbara J., Wende, Karl, Weinstock-Guttman, Bianca, Whitham, Ruth H.

“…Background and objective: This report provides results of CSF analyses done in a subset of relapsing remitting MS patients participating in a…”
Get full text

Eight-year immunogenicity and safety of interferon beta-1a-Avonex registered treatment in patients with multiple sclerosis by Herndon, R M, Rudick, R A, Munschauer, FE III, Mass, M K, Salazar, A M, Coats, ME, Labutta, R, Richert, J R, Cohan, S L, Genain, C, Goodkin, D, Toal, M, Riester, K

“…An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFN beta -1a-Avonex) was conducted to evaluate the immunogenicity and…”
Get full text

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis: Multiple sclerosis by RUDICK, R. A, GOODKIN, D. E, ALAM, J. J, SIMONIAN, N. A, CAMPION, M. K, BARTOSZAK, D. M, BOURDETTE, D. N, BRAIMAN, J, BROWNSCHEIDLE, C. M, COATS, M. E, COHAN, S. L, DOUGHERTY, D. S, JACOBS, L. D, KINKEL, R. P, MASS, M. K, MUNSCHAUER, F. E, PRIORE, R. L, PULLICINO, P. M, SCHEROKMAN, B. J, WEISTOCK-GUTTMAN, B, WHITHAM, R. H, COOKFAIR, D. L, HERNDON, R. M, RICHERT, J. R, SALAZAR, A. M, FISCHER, J. S, GRANGER, C. V, SIMON, J. H

Get full text

Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals by Martin, A, Heyes, M P, Salazar, A M, Kampen, D L, Williams, J, Law, W A, Coats, M E, Markey, S P

“…Neuropsychological functioning and cerebrospinal fluid concentrations of an endogenous neurotoxin, quinolinic acid (QUIN) were evaluated in 52 HIV-positive…”
Get more information

Results of an Ongoing, Open-Label, Safety-Extension Study of Interferon Beta-1a (Avonex) Treatment in Multiple Sclerosis by Herndon, RM, Jacobs, LD, Coats, ME, Goodkin, DE, Mass, MK, Richert, JR, Rudick, RA, Waubant, EL, Weinstock-Guttman, B, Scaramucci, JO, Burnett, BK, Jones, WE, Simonian, NA

“…Abstract In a phase III, double-blind, placebo-controlled, 2-year clinical trial, interferon beta-1a (IFN-β-1a, Avonex) treatment significantly delayed…”
Get full text

Meige's disease and a positive treatment response with deanol by Coats, M E

Get more information

Evaluation of the Charcoal Card Test for Trichinosis in Swine by Coats, M. E., Leland, S. E., Kelley, D. C.

Get full text